<DOC>
	<DOCNO>NCT00664417</DOCNO>
	<brief_summary>Following licensure sanofi pasteur 's 90 µg rgA/Vietnam/1203/2004 pandemic influenza vaccine , effort develop low antigen dose formulation improve immunogenicity use adjuvant initiate . The present study part endeavor . It primarily formulation/dose-finding study secondary aim generate safety immunogenicity data final formulation development pre-pandemic vaccine .</brief_summary>
	<brief_title>Study Different Formulations Intramuscular A/H5N1 Inactivated , Split Virion Influenza Adjuvanted Vaccine</brief_title>
	<detailed_description>This Phase I , observer-blinded , randomize , control multicenter , dose-finding study adult subject . All vaccine administer two-dose schedule ( H5N1 ) immunologically-naïve adult . Immunogenicity safety evaluate injection .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Orthomyxoviridae Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Healthy adult age 18 40 year day inclusion . Provides sign informed consent prior study procedure . Able attend schedule visit comply trial procedure . For woman childbearing potential , avoid become pregnant ( use effective method contraception abstinence ) least 4 week prior first vaccination , least 4 week last vaccination . Exclusion Criteria : Known systemic hypersensitivity vaccine component history lifethreatening reaction standarddose Fluzone® vaccine vaccine contain substance For woman childbearing potential , known pregnancy positive serum/urine pregnancy test Breast feeding woman Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede ( first ) trial vaccination Planned participation another clinical trial present trial period Known suspect congenital acquire immunodeficiency , immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month , oral , parenteral , inhaled steroid Has acute chronic medical illness condition would , opinion site investigator , place subject unacceptable risk injury would interfere evaluation response render subject unable meet requirement protocol Known suspect current alcohol abuse drug addiction may interfere subject 's ability comply trial procedure History receipt blood immunoglobulin bloodderived product within 3 month prior enrollment study might interfere assessment immune response Receipt vaccine 4 week precede first trial vaccination Planned receipt vaccine 4 week precede follow trial vaccination Known Human Immunodeficiency Virus ( HIV ) , Hepatitis B surface antigen , Hepatitis C seropositivity Personal family history GuillainBarré Syndrome Thrombocytopenia , bleed disorder anticoagulant 3 week precede inclusion contraindicate IM vaccination Active neoplastic disease history hematologic malignancy Previous participation pandemic flu trial History H5N1 infection exposure presumed/confirmed H5N1 human/animal case Known seizure/epilepsy history and/or take antiseizure medication Receipt psychiatric drug . Subjects receive single antidepressant drug stable least 3 month prior enrollment , without decompensating symptom allow enroll study . Subject deprive freedom administrative court order , emergency setting , hospitalize without his/her consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Influenza</keyword>
	<keyword>A/H5N1</keyword>
	<keyword>Orthomyxoviridae Infections</keyword>
	<keyword>Influenza Pandemics</keyword>
</DOC>